Talk Presenting Companies (Theatre A) track
Oncology: Ymmunobio AG
Mon, Nov 9, 2026 · 1:30–1:45 PM CET Koelnmesse
About this session
Ymmunobio is a preclinical-stage oncology company advancing a first-in-class ADC treatment solution based on the proprietary tumor specific antigen (TSA) NPTXR, a neo-expressed membrane protein found exclusively on cancer cells. The company's lead asset, YB-811, a dual payload Antibody Drug Conjugate (ADC), is designed to selectively target NPTXR-positive tumors with no off-tumor toxicity risk, leveraging third-generation linker-payload chemistry for superior safety and efficacy.
Speaker
-
CEO · Ymmunobio AG
Speaker